Chronological age versus biological age skin#

Signal joint T-cell receptor rearrangement excision circle telomeres DNA-methylation gene expression cellular senescence aging 1. This is based on the observation that there are individual differences in age-associated decline in performance that are reflected by measurable biological indicators, such as telomere length, signal joint T-cell receptor rearrangement excision circles, and specific DNA-methylation and gene expression events. In the present article, we develop the hypothesis that age-dependent preventative measures and diagnostic screenings might perform better if biological age were used instead of chronological age. They likely contribute to the observed increase in life expectancy through the reduction of incidence and the retardation of the onset of age-associated diseases. Primary prevention and early diagnosis of these diseases have a dramatic impact on incidence, outcome, quality of life and are commonly applied as age-dependent indications based on evidence of efficacy for specific groups of the aging population. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.Īging is associated with an increased incidence of major diseases, including cancer, cardiovascular, neurodegenerative, metabolic and autoimmune diseases. Biological Age versus Chronological Age in the Prevention of Age Associated Diseases. Recommended citation: Rollandi GA, Chiesa A, Sacchi N, Castagnetta M, Puntoni M, Amaro A, Banelli B, Pfeffer U. Received: Janu| Accepted: Ap| Published: May 05, 2019 Special Issue: Perspectives on Telomeres and Aging * Correspondences: Gian Andrea Rollandi, Ulrich Pfeffer IRCCS Ospedale Policlinico San Martino, Genova, Italy Ente Ospedaliero Ospedali Galliera, Genova, ItalyĢ. Gian Andrea Rollandi 1, *, Aldo Chiesa 1, Nicoletta Sacchi 1, Mauro Castagnetta 1, Matteo Puntoni 1, Adriana Amaro 2, Barbara Banelli 2, Ulrich Pfeffer 2, *ġ. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

The journal publishes research articles, reviews, communications and technical notes. Papers must be clear and concise, but detailed data is strongly encouraged.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21 st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm. Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches.

Chronological age versus biological age skin#

We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases. OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases.